ECM
SKYE icon

ExodusPoint Capital Management’s Skye Bioscience SKYE Stock Holding History

ExodusPoint Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-24,552
Closed -$96K – 2157
2024
Q3 		$96K Buy
+24,552
New +$138K ﹤0.01% 1513

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

ExodusPoint Capital Management's SKYE Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Skye Bioscience (SKYE) in Q4 2024, closing a stake of 24,552 shares — an estimated $96K sold.

ExodusPoint Capital Management first reported a position in SKYE in Q3 2024 and held it in 1 quarter. The position peaked at $96K in Q3 2024. 73 funds tracked by Wall St. Rank hold SKYE as of Q4 2024.

  • ExodusPoint Capital Management reported no remaining Skye Bioscience position as of Q4 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 24,552 Skye Bioscience shares in Q4 2024, an estimated $96K.
  • ExodusPoint Capital Management first reported a position in Skye Bioscience in Q3 2024 and held it in 1 quarter.
  • ExodusPoint Capital Management's Skye Bioscience position peaked at $96K in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.